Progress and prospects: immune responses to viral vectors
- 12 November 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Gene Therapy
- Vol. 17 (3), 295-304
- https://doi.org/10.1038/gt.2009.148
Abstract
Viral vectors are potent gene delivery platforms used for the treatment of genetic and acquired diseases. However, just as viruses have evolved to infect cells efficiently, the immune system has evolved to fight off what it perceives as invading pathogens. Therefore, innate immunity and antigen-specific adaptive immune responses against vector-derived antigens reduce the efficacy and stability of in vivo gene transfer. In addition, a number of vectors are derived from parent viruses that humans encounter through natural infection, resulting in preexisting antibodies and possibly in memory responses against vector antigens. Similarly, antibody and T-cell responses may be directed against therapeutic gene products that often differ from the endogenous nonfunctional or absent protein that is being replaced. As details and mechanisms of such immune reactions are uncovered, novel strategies are being developed, and vectors are being specifically engineered to avoid, suppress or manipulate the response, ideally resulting in sustained expression and immune tolerance to the transgene product. This review provides a summary of our current knowledge of the interactions between the immune system adeno-associated virus, adenoviral and lentiviral vectors, and their transgene products.Keywords
This publication has 69 references indexed in Scilit:
- Activation of Transgene-specific T Cells Following Lentivirus-mediated Gene Delivery to Mouse LungMolecular Therapy, 2010
- New Insights on Adenovirus as Vaccine VectorsMolecular Therapy, 2009
- Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humansNature Medicine, 2009
- Baseline Ad5 serostatus does not predict Ad5 HIV vaccine–induced expansion of adenovirus-specific CD4+ T cellsNature Medicine, 2009
- Transient Pretreatment With Glucocorticoid Ablates Innate Toxicity of Systemically Delivered Adenoviral Vectors Without Reducing EfficacyMolecular Therapy, 2009
- Striatal Readministration of rAAV Vectors Reveals an Immune Response Against AAV2 Capsids That Can Be CircumventedMolecular Therapy, 2009
- Detection of Intact rAAV Particles up to 6 Years After Successful Gene Transfer in the Retina of Dogs and PrimatesMolecular Therapy, 2009
- Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expressionVirology, 2008
- Diverse IgG subclass responses to adeno‐associated virus infection and vector administrationJournal of Medical Virology, 2008
- Effect of Gene Therapy on Visual Function in Leber's Congenital AmaurosisThe New England Journal of Medicine, 2008